| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Investment loss from eton pharmaceuticals | - | 0 | ||
| Total other expense, net | -13,727 | -6,414 | ||
| Income (loss) before income taxes | 1,020 | 4,995 | ||
| Income tax expense | - | 0 | ||
| Net income (loss) | 1,020 | 4,995 | ||
| Basic net income (loss) per share of common stock | 0.03 | 0.14 | ||
| Diluted net income (loss) per share of common stock | 0.03 | 0.13 | ||
| Weighted average number of shares of common stock outstanding, basic | 37,145,440 | 36,790,306 | ||
| Weighted average number of shares of common stock outstanding, diluted | 38,875,005 | 38,853,855 | ||
HARROW, INC. (HROWL)
HARROW, INC. (HROWL)